Nasdaq GlobeNewswire

Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK(TM) (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting

Del
  • Study met primary endpoint (p=0.0033)
  • Significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with Standard Risk Hepatoblastoma (SR-HB)
  • Company plans to pursue regulatory approvals with FDA and EMA

RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today data from its Phase 3 SIOPEL 6 study presented during the late breaker session on Saturday, October 14, 2017 at SIOP 2017 in Washington, DC.

Top Line Efficacy Data

The SIOPEL 6 study met its primary endpoint.  The study demonstrated that the addition of STS significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumour protection. Among the 99 evaluable patients, hearing loss occurred in 30/45=67% treated with Cisplatin (Cis) alone and in 20/54=37.0% treated with Cis+STS, corresponding to a relative risk of 0.56(P=0.0033).

Fennec plans to pursue regulatory approval for PEDMARKTM based on the data from the SIOPEL 6 study along with the proof of principle data from COG ACCL0431. STS has received Orphan Drug Designation in the US in this setting and plans to pursue European Market Exclusivity for Pediatric Use upon approval.

"I am absolutely delighted that after 30 years of research we have found a safe way to reduce ototoxicity in children receiving platinum containing chemotherapy," said Penelope Brock, M.D., PhD, International Chair of SIOPEL. "This means that children who are cured from cancer after receiving platinum treatment can look forward to a normal healthy life, fully integrated into society. I believe this marks a new standard of care in pediatric oncology."

The Company also reported top-line data for secondary endpoints Event Free Survival (EFS) and Overall Survival (OS). The combination of Cis+STS was generally well tolerated. With a follow up of 52 months, 3yr EFS is Cis 78.8% and Cis+STS 82.1%; 3yr OS is Cis 92.3% and Cis+STS 98.2%.

"We are very pleased with the results of this study," stated Rosty Raykov, CEO of Fennec. "We would like to thank all the patients and their families who participated in this trial, physicians, the entire SIOPEL 6 team, and Dr. Neuwelt and his research team at OHSU. We believe that if approved PEDMARK would be an important therapy for patients and caregivers where currently there are no treatment options."

Safety and Tolerability

In the study, the results presented showed that treatment was well tolerated and acute toxicity similar and expected between arms. The table below presents the toxicities of the two arms: 

Adverse event Grade CIS   CIS+STS  
    N % N %
Febrile neutropenia

3 7 13.5 5 8.8
4 - - - -
Infection

3 5 9.6 6 10.5
4 - - - -
Hypomagnesemia

3 1 1.9 1 1.8
4 - - - -
Hypernatremia

3 - - 1 1.8
4 - - - -
Vomiting

3 1 1.9 3 5.3
4 - - - -
Nausea

3 3 5.8 2 3.5
4 - - - -

SIOP 2017 Presentation

Fennec will provide access to the recording of SIOP 2017 late breaker presentation on the Company's website.

To access the archived recording, visit the Fennec website at www.fennecpharma.com.

SIOPEL 6

SIOPEL 6 is a multi-centre open label randomized phase 3 study evaluating the efficacy of STS in reducing ototoxicity in patients receiving cisplatin monotherapy for standard risk hepatoblastoma.  From the beginning of 2007 to the end 2014, 52 sites from 11 countries enrolled 113 evaluable patients.  The study is closed to recruitment and all protocol pre-specified IDMC safety reviews are now complete.  The primary efficacy hearing endpoint analysis can be performed once patients have reached 3.5 years of age and an audiometry test can be carried out. The SIOPEL 6 study trial was designed with 80% power and a 5% significance level to detect an absolute 25% reduction in the rate of Brock grade greater than or equal to 1 hearing loss with a chi-square test, from a 60% hearing loss in Cis alone arm to a 35% hearing loss in Cis+STS arm. The primary endpoint is the rate of Brock grade greater than or equal to 1 hearing loss determined after the end of treatment at the age of greater than or equal to 3.5 years by pure tone audiometry.

About PEDMARKTM (sodium thiosulfate/STS)

Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies.  Unfortunately, platinum-based therapies cause ototoxicity in many patients, and are particularly harmful to the survivors of pediatric cancer.

In the U.S. and Europe there is estimated that over 7,000 children are diagnosed with local cancers that may receive platinum-based chemotherapy. Localized cancers that receive platinum agents may have overall survival rates of greater than 80% further emphasizing the quality of life after treatment. The incidence of hearing loss in these children depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.

STS has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies are closed to recruitment. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma.  SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors. COG ACCL0431 final results were published in the Lancet Oncology.

In May 2017, Fennec announced the launch of a Named Patient Program in Europe. European based Healthcare Professionals can obtain details about STS Named Patient Program by emailing clinical@fennecpharma.com.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., is a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients. STS has received Orphan Drug Designation in the US in this setting. Fennec has an exclusive license agreement with OHSU for exclusive worldwide license rights to intellectual property directed to STS and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit www.fennecpharma.com.

Forward looking statements

Except for historical information described in this press release, all other statements are forward-looking. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2016. Fennec Pharmaceuticals, Inc. disclaims any obligation to update these forward-looking statements except as required by law.

The scientific information discussed in this news release related to PEDMARKTM is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, Health Canada or other regulatory and no conclusions can or should be drawn regarding the safety or effectiveness of such product candidate.

For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

For further information, please contact:

Rosty Raykov
Chief Executive Officer
Fennec Pharmaceuticals Inc.
T: (919) 636-5144




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Fennec Pharmaceuticals via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

INTA Selects Singapore for 142nd Annual Meeting Slated for April 202021.5.2018 02:10Pressemelding

SEATTLE, May 20, 2018 (GLOBE NEWSWIRE) -- The International Trademark Association (INTA) today announced that it will hold its 142nd Annual Meeting-the world's largest trademark event-in Singapore from April 25 to 29, 2020, at the Marina Bay Sands. This marks the second time INTA is bringing its Annual Meeting to Asia, and the first time that the organization will host the event in Southeast Asia. INTA CEO Etienne Sanz de Acedo made the highly anticipated announcement at the opening ceremonies of the Association's 140th Annual Meeting, taking place in Seattle, Washington, now through May 23. Nearly 11,000 trademark practitioners and other intellectual property (IP) professionals from 150+ countries are gathering for this event. The number of registrants has been increasing each year. In 2014, INTA held its first-ever Annual Meeting in Asia-the 136th Annual Meeting in Hong Kong SAR, China. After that successful event, INTA's Board of Directors approved a rotation strategy to host the An

GlobeNewswire Test Release19.5.2018 07:00Pressemelding

LOS ANGELES, May 18, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Director, GlobeNewswire Product Management Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or Magali Rolandez Senior Manager, Media Relations/Content Distribution Europe Direct: +44 (0) 203 753 2215 Mobile: +44 (0) 7785 619 539

BK Ultrasound, Powered by Analogic, Launches bkSpecto Ultrasound System for Urology at the 2018 American Urological Association Annual Meeting18.5.2018 23:23Pressemelding

PEABODY, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, today announced that it will launch the bkSpecto(TM) ultrasound system at the 113th AUA (American Urological Association) Annual Meeting, May 18-21, in San Francisco. bkSpecto-taken from the Latin word Specto, meaning 'I see'-is BK Ultrasound's all-new ultrasound platform designed for clinical practices. bkSpecto combines BK's advanced auto-optimization algorithms with faster processing to render exceptional anatomical imaging detail with minimal manual adjustment by the user. The system has a unique glass touch-based interface using BK's Tru-Sense(TM) technology to provide 'sightless navigation.' The interface enables tactile feedback with or without gloves, providing an intuitive, self-guided user experience. The interface is also customizable, enabling personalized and faster user workflows. The small footprint of bkSpecto makes

Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid18.5.2018 12:55Pressemelding

TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE:BAM) (TSX:BAM.A) (EURONEXT:BAMA) ("Brookfield") today announced it has received approval from the Toronto Stock Exchange ("TSX") for the renewal of its normal course issuer bid to purchase up to 82,315,909 Class A Limited Voting Shares ("Class A Shares"), representing 10% of the public float of Brookfield's outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange ("NYSE") and any alternative Canadian trading system. The period of the normal course issuer bid will extend from May 24, 2018 to May 23, 2019, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased. As at May 1, 2018, the number of Class A Shares issued and outstanding totalled 991,857,711, of which 823,159,095 shares represented the public float. In accordance with the rules

Skybox Security and Exclusive Networks Announce New Partnership for Middle East Distribution of the Skybox Security Suite17.5.2018 18:41Pressemelding

The cybersecurity management platform ensures networks remain secure and compliant as organisations migrate to cloud and merge networks SAN JOSE, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Skybox(TM) Security, a global leader in cybersecurity management, announced today a new partnership with Exclusive Networks for distribution of Skybox solutions in the Middle East, including the Gulf Cooperation Council (GCC) region and Egypt. Exclusive Networks will deploy and service the Skybox(TM) Security Suite, a broad security management platform that provides comprehensive attack surface visibility and enables unified vulnerability management and firewall/security policy management across an organization's entire network, including in physical, multi-cloud and OT environments. "Driven by government outlays (with oil, gas and defence industries leading the charge), Middle East organisations are looking for trusted security advisors who can navigate digital transformations and reduce risks - espec

Dermatological Symposium Tackles the Effects of Pollution on Skin17.5.2018 16:03Pressemelding

Researchers Present Compelling Evidence Showing the Effects of Pollution on Skin Health at Symposium Sponsored by Mary Kay Inc. DALLAS, May 17, 2018 (GLOBE NEWSWIRE) -- Mary Kay Inc. announced four keynote speakers for its symposium to be held during the prestigious International Investigative Dermatology (IID) Meeting on May 16 to 19, 2018 in Orlando, Florida. The IID meeting occurs once every 5 years, and brings together scientists from across the globe, highlighting the latest in cutting edge science in dermatology. The Mary Kay sponsored Symposium features four global experts including Dr. Liang Liu, Assistant Professor of Dermatology, Columbia University; Dr. Max Costa, Professor and Chairman of the department of Environmental Medicine, New York University School of Medicine; Dr. Jean Krutmann, Chair of Environmental Medicine at the Medical Faculty of Heinrich Heine University Düsseldorf and Director of the Leibniz Research Institute of Environmental Medicine in Dusseldorf, German

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom